U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H17N3O7S2
Molecular Weight 427.452
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFOXITIN

SMILES

CO[C@]2(NC(=O)CC1=CC=CS1)[C@H]3SCC(COC(N)=O)=C(N3C2=O)C(O)=O

InChI

InChIKey=WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1

HIDE SMILES / InChI
Molecular Formula C16H17N3O7S2
Molecular Weight 427.452
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/cefoxitin.html

Cefoxitin is a cephamycin antibiotic often grouped with the second-generation cephalosporins. It is active against a broad range of gram-negative bacteria including anaerobes. The methoxy group in the 7a position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria. The bactericidal action of cefoxitin results from inhibition of cell wall synthesis.

CNS Activity

Originator

Approval Year

1978
88
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Klebsiella pneumoniae growth
4
Target ID: Klebsiella pneumoniae growth
Inhibitor
8504
D-alanyl-D-alanine carboxypeptidase DacC
3
Target ID: P08506
Gene ID: 945455.0
Gene Symbol: dacC
Target Organism: Escherichia coli (strain K12)
Inhibitor
8504
D-alanyl-D-alanine carboxypeptidase DacA
4
Target ID: P0AEB2
Gene ID: 945222.0
Gene Symbol: dacA
Target Organism: Escherichia coli (strain K12)
Inhibitor
8504
D-alanyl-D-alanine endopeptidase
2
Target ID: P0AFI5
Gene ID: 946662.0
Gene Symbol: pbpG
Target Organism: Escherichia coli (strain K12)
Inhibitor
8504
Penicillin-binding protein 1B
22
Target ID: P02919
Gene ID: 944843.0
Gene Symbol: mrcB
Target Organism: Escherichia coli (strain K12)
Inhibitor
8504
Penicillin-binding protein 2B
10
Target ID: P0A3M6
Gene ID: 933948.0
Gene Symbol: penA
Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Inhibitor
8504
 8.0 nM [IC50]
Penicillin-binding protein 1A
45
Target ID: Q8DR59
Gene ID: 934791.0
Gene Symbol: pbpA
Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Inhibitor
8504
 6.8 nM [IC50]
penicillin-binding protein 2A
2
Target ID: 933569.0
Gene Symbol: pbp2a
Inhibitor
8504
 2.4 nM [IC50]
penicillin-binding protein 1B
2
Target ID: 934893.0
Gene Symbol: pbp1b
Inhibitor
8504
 0.145 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

2010
Curative
Approved
8583
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

2010
Curative
Approved
8583
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

2010
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
24 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/318227/
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
33.5 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/318227/
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.67 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/318227/
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
27%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/318227/
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g single, intramuscular
Dose: 2 g
Route: intramuscular
Route: single
Dose: 2 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/3578148
unhealthy, 17 years
Health Status: unhealthy
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3578148
Disc. AE: Hoigne's syndrome...
AEs leading to
discontinuation/dose reduction:
Hoigne's syndrome (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3578148
12 g 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/318219
unhealthy, 22 years
Health Status: unhealthy
Age Group: 22 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/318219
Sources:
https://pubmed.ncbi.nlm.nih.gov/318219
2 g 3 times / day multiple, intravenous
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21042010
unhealthy, 45 years
Health Status: unhealthy
Age Group: 45 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21042010
Disc. AE: Hemolytic anemia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21042010
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
unhealthy, 77 years
Health Status: unhealthy
Age Group: 77 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
Disc. AE: Hemolytic anemia, Pancytopenia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia (1 patient)
Pancytopenia (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
AEs

AEs

AESignificanceDosePopulation
Hoigne's syndrome 1 patient
Disc. AE
2 g single, intramuscular
Dose: 2 g
Route: intramuscular
Route: single
Dose: 2 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/3578148
unhealthy, 17 years
Health Status: unhealthy
Age Group: 17 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3578148
Hemolytic anemia 1 patient
Disc. AE
2 g 3 times / day multiple, intravenous
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21042010
unhealthy, 45 years
Health Status: unhealthy
Age Group: 45 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21042010
Hemolytic anemia 1 patient
Disc. AE
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
unhealthy, 77 years
Health Status: unhealthy
Age Group: 77 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
Pancytopenia 1 patient
Disc. AE
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
unhealthy, 77 years
Health Status: unhealthy
Age Group: 77 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:209807
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:209807
ChemicalBook
CB9490581
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9490581
MolPort
MolPort-006-127-091
https://www.molport.com/shop/molecule-link/MolPort-006-127-091
ZINC
ZINC000003830449
http://zinc15.docking.org/substances/ZINC000003830449
PubMed

PubMed

TitleDatePubMed
Multiple antibiotic-resistance mechanisms including a novel combination of extended-spectrum beta-lactamases in a Klebsiella pneumoniae clinical strain isolated in Argentina.
2003-07
Sequence analysis and biochemical characterisation of chromosomal CAV-1 (Aeromonas caviae), the parental cephalosporinase of plasmid-mediated AmpC 'FOX' cluster.
2003-05-16
A seven-year survey of Klebsiella pneumoniae producing TEM-24 extended-spectrum beta-lactamase in Nice University Hospital (1994-2000).
2003-05
Automated ribotyping and pulsed-field gel electrophoresis for rapid identification of multidrug-resistant Salmonella serotype newport.
2003-04
Natural antimicrobial susceptibilities of strains of 'unusual' Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea.
2003-04
Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease.
2003-03-15
Group 1 beta-lactamases of Aeromonas caviae and their resistance to beta-lactam antibiotics.
2003-03
Isolation of Escherichia coli O157:H7 from intact colon fecal samples of swine.
2003-03
Emergence of ceftriaxone-resistant Salmonella isolates and rapid spread of plasmid-encoded CMY-2-like cephalosporinase, Taiwan.
2003-03
Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period.
2003-03
Faropenem, a new oral penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates.
2003-03
[Activity of 14 antimicrobials against Eikenella corrodens].
2003-02-26
Pelvic inflammatory disease: how should it be managed?
2003-02
Occurrence and detection of AmpC beta-lactamases among Gram-negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur Hospital, Delhi, India.
2003-02
Endometritis does not predict reproductive morbidity after pelvic inflammatory disease.
2003-01
Antibiotic resistance of Neisseria gonorrhoeae in Spain: trends over the last two decades.
2003-01
Beta-lactamase characterization in Escherichia coli isolates with diminished susceptibility or resistance to extended-spectrum cephalosporins recovered from sick animals in Spain.
2003
High-dose antibiotic therapy is superior to a 3-drug combination of prostanoids and lipid A derivative in protecting irradiated canines.
2002-12
Increase in resistance to new fluoroquinolones from 1998 to 2001 in the Bacteroides fragilis group.
2002-12
Antibacterial activity of moxifloxacin against periodontal anaerobic pathogens involved in systemic infections.
2002-12
beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin.
2002-11
Comparison of screening methods for TEM- and SHV-derived extended-spectrum beta-lactamase detection.
2002-11
Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection.
2002-11
Further modification of the Hodge test to screen AmpC beta-lactamase (CMY-1)-producing strains of Escherichia coli and Klebsiella pneumoniae.
2002-11
Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection.
2002-10-01
Epidemiological and antibiotic resistant study on extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Zhejiang Province.
2002-10
[Trends in antimicrobial utilization in a university hospital, 1990-1996].
2002-10
Natural antibiotic susceptibility of Enterobacter spp., with special reference to Enterobacter aerogenes and Enterobacter intermedius strains.
2002-10
Nontuberculous mycobacterial pulmonary diseases in immunocompetent patients.
2002-09-25
Selection of cefoxitin-resistant bacteroides thetaiotaomicron mutants and mechanisms involved in beta-lactam resistance.
2002-09-01
Multilaboratory comparison of anaerobe susceptibility results using 3 different agar media.
2002-09-01
Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains.
2002-09
Klebsiella and enterobacter: antibiotic resistance and treatment implications.
2002-09
Susceptibility to antibiotics and biochemical properties of Desulfovibrio desulfuricans strains.
2002-08-29
Klebsiella pneumoniae: epidemiology and analysis of risk factors for infections caused by resistant strains.
2002-08
Cross-reactivity of cefotetan and ceftriaxone antibodies, associated with hemolytic anemia, with other: cephalosporins and penicillin.
2002-08
Comparison of several methods used for the determination of cephalosporins. Analysis of cephalexin in pharmaceutical samples.
2002-07-01
Occurrence and characterization of resistance to extended-spectrum cephalosporins mediated by beta-lactamase CMY-2 in Salmonella isolated from food-producing animals in Canada.
2002-07
Outbreak of multidrug-resistant Salmonella newport--United States, January-April 2002.
2002-06-28
Outpatient pelvic inflammatory disease treatment as effective as inpatient care, study finds.
2002-06-14
Clinical review: bacteremia caused by anaerobic bacteria in children.
2002-06
Characterization of cefotaxime-resistant Escherichia coli isolates from a nosocomial outbreak at three geriatric hospitals.
2002-06
[Genotypic exploration of a hospital neonatal outbreak due to Klebsiella pneumoniae producing extended-spectrum-betalactamase].
2002-05
Proposed protocol to reduce bacterial infectious complications in living related small bowel transplant recipients.
2002-05
Antibiotic sensitivities of common bacterial pathogens in urinary tract infections at Gondar Hospital, Ethiopia.
2002-03
Escherichia coli isolated from seafood: toxicity and plasmid profiles.
2002-03
[Extended-spectrum beta-lactamase detection in Enterobacteriaceae and antibiotic susceptibility analysis].
2002-02-28
[Multidrug resistance in Klebsiella pneumoniae: multicenter study].
2002-01
Influence of failure of primary wound healing on subsequent recurrence of pilonidal sinus. combined prospective study and randomised controlled trial.
2002
A clinical strain of Escherichia coli possessing CMY-2 plasmid-mediated amp C beta-lactamase: an emerging concern in pediatrics?
2002
Patents

Patents

07662955
9
JP2001500477A
122
JP2002541113A
46
JP2003515526A
470
JP2009541210A
80
JP2011528275A
456
JP4718445B2
36
JP4763957B2
87
JP4792032B2
112
JP4849764B2
75
JPH03279329A
9
JPS06143116A
2
JPS5583791A
2
JPS5711917A
2
JPS5942317A
6
JPS6143116A
2

Sample Use Guides

In Vivo Use Guide
Adults The usual adult dosage range is 1 gram to 2 grams every six to eight hours.
Route of Administration: Intravenous
In Vitro Use Guide
CEFOXITIN inhibited Mycobacterium fortuitum growth with MIC 32 ug/ml
Substance Class Chemical
Created
by admin
on Wed Apr 02 08:45:38 GMT 2025
Edited
by admin
on Wed Apr 02 08:45:38 GMT 2025
Record UNII
6OEV9DX57Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
J01DC01
Preferred Name English
CEFOXITIN
INN   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
(6R,7S)-3-(Hydroxymethyl)-7-methoxy-8-oxo-7-[2-(2-thienyl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid carbamate (ester)
Systematic Name English
CEFOXITIN [USAN]
Common Name English
Cefoxitin [WHO-DD]
Common Name English
CEFOXITIN [VANDF]
Common Name English
CEFOXITIN [USP-RS]
Common Name English
CEFOXITIN [ORANGE BOOK]
Common Name English
CEFOXITIN [MI]
Common Name English
cefoxitin [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011161
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
NDF-RT N0000011161
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
NDF-RT N0000011161
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
NDF-RT N0000011161
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
LIVERTOX NBK548666
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
NDF-RT N0000011161
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
NDF-RT N0000011161
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
WHO-VATC QJ01DC01
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
NDF-RT N0000011161
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
NDF-RT N0000175488
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
NDF-RT N0000011161
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
NDF-RT N0000011161
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
NCI_THESAURUS C357
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
NDF-RT N0000011161
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
LIVERTOX NBK547862
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
NDF-RT N0000011161
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
NDF-RT N0000011161
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
WHO-ATC J01DC01
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL996
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
MERCK INDEX
m3208
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY Merck Index
DRUG CENTRAL
550
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
RS_ITEM_NUM
1098107
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
ECHA (EC/EINECS)
252-641-2
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
CAS
35607-66-0
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
DAILYMED
6OEV9DX57Y
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
WIKIPEDIA
CEFOXITIN
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
LACTMED
Cefoxitin
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
INN
3397
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
EVMPD
SUB07409MIG
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
CHEBI
209807
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
MESH
D002440
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
RXCUI
2189
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY RxNorm
FDA UNII
6OEV9DX57Y
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
SMS_ID
100000081807
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
DRUG BANK
DB01331
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
NCI_THESAURUS
C61665
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
EPA CompTox
DTXSID1022764
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
PUBCHEM
441199
Created by admin on Wed Apr 02 08:45:38 GMT 2025 , Edited by admin on Wed Apr 02 08:45:38 GMT 2025
PRIMARY
Related Record Type Details
Structure of CEFOXITIN SODIUM
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of CEFOXITIN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966